Tonix Pharmaceuticals Holding Corp. TNXP R2K

Q: What is the current share price of Tonix Pharmaceuticals Holding Corp. (TNXP)?

As of 2026-07-14 21:23 PDT, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at $11.06 on NasdaqGS. Its 52-week range is $10.65 to $61.57.

Q: What is the market capitalisation of TNXP?

Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalisation of $176.31M on NasdaqGS.

Q: What is the P/E ratio of TNXP?

TNXP trades at a trailing price-to-earnings (P/E) ratio of -0.75. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.59.

Q: What is the return on equity (ROE) of TNXP?

TNXP has a return on equity (ROE) of -72.33%. Its return on capital employed (ROCE) is -51.03%.

Q: Is TNXP a good stock to buy?

This page provides a data-driven analysis of Tonix Pharmaceuticals Holding Corp. (TNXP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.tonixpharma.com

Company Profile ↓

$11.06

-74.15% 1Y

Mkt Cap$176.31M

P/E-0.75

P/B0.59

52W High$61.57

52W Low$10.65

Book Value$19.17

EPS (TTM)$-14.66

Company Overview

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 29.9% CAGR over the past five years.

Recent Developments

Dec 2025 Revenue of $13.11M (+29.8% YoY); net profit $-124.02M.
Trailing 12 Months Year-on-year growth — revenue +183.2%.
5-Year Trend Long-term compounding — revenue CAGR 29.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	29.90%
1 Year:	183.20%

Stock Price Performance

1 Year:	-74.15%
6 Months:	-28.55%
3 Months:	-14.79%
1 Month:	+3.85%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 1% of range

$10.65 $61.57

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)37.93 · Neutral

Price Performance

1M+3.85%

3M-14.79%

6M-28.55%

1Y-74.15%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 29.9% over 5 years.

CONS

Trading 82.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.75

Industry PE

25.41

Forward P/E

-1.42

PEG Ratio

Book Value

$19.17

Price to Book

0.59

P/S

10.31

EV/EBITDA

0.02

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

29.90%

Profit 5Y

Revenue (YoY)

183.20%

Earnings (YoY)

Profitability & Returns

ROCE

-51.03%

ROE

-72.33%

ROA

-41.92%

Profit Margin

0.00%

Op Margin

Gross Margin

58.56%

EPS (Latest Qtr)

$-2.93

EPS (TTM)

$-14.66

Balance Sheet & Liquidity

Debt/Equity

0.57

Quick Ratio

6.57

Current Ratio

6.99

Debt

$1.29M

Total Assets

$257.91M

Current Assets

Working Capital

Ownership

Promoter Holding

0.13%

Chg in Prom Hold

FII / Inst Holding

45.54%

Chg in FII Hold

-0.10%

Financial Snapshot

Enterprise Value

$176.31M

Total Revenue (TTM)

$17.56M

EBITDA

$-149.20M

Free Cash Flow

$-76.73M

Operating Cash Flow

$-125.58M

Shares Outstanding

15.94M

Gross Margin

58.56%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TNXP Tonix Pharmaceuticals Holding Corp. R2K	11.06	-0.75	$176.31M	0.00%	-51.03%	-72.33%	29.90%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.99M	2.48M	2.21M	2.82M	2.43M	2.00M	3.29M	6.88M
Operating Income	-3.09M	-5.17M	-6.05M	-7.43M	-9.00M	-9.70M	-11.78M	-13.28M	-13.40M	-14.01M	-9.84M	-7.61M	-5.09M	-4.82M	-5.83M	-6.99M	-6.14M	-5.54M	-6.30M	-5.91M	-7.89M	-7.30M	-14.19M	-12.00M	-20.74M	-23.56M	-18.54M	-26.44M	-23.34M	-29.59M	-33.90M	-29.00M	-28.15M	-21.35M	-77.32M	-15.55M	-16.05M	-28.30M	-33.07M	-41.54M
Net Income	-3.09M	-5.16M	-6.04M	-7.42M	-8.99M	-9.68M	-11.76M	-13.25M	-13.36M	-13.98M	-9.81M	-7.58M	-5.06M	-4.78M	-5.79M	-6.93M	-6.09M	-5.48M	-6.23M	-5.84M	-7.84M	-7.27M	-14.18M	-11.99M	-20.65M	-23.55M	-18.53M	-26.42M	-23.14M	-28.98M	-33.01M	-28.36M	-27.98M	-14.94M	-78.78M	-14.21M	-16.83M	-28.27M	-32.01M	-40.19M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.07	-2.25	-1.60	-1.61	-7.64	-4.24	-3.21	-49.23	-38.63	-535.72	-1,920.85	-22.68	-2.84	-3.86	-3.59	-2.93
R&D Expense	1.64M	3.55M	4.08M	5.22M	-	6.83M	8.87M	10.31M	-	10.67M	7.52M	5.47M	2.99M	2.81M	3.91M	5.17M	4.07M	3.26M	3.90M	3.55M	5.05M	4.68M	10.57M	8.81M	15.33M	18.13M	13.08M	18.42M	16.58M	22.20M	26.51M	21.98M	21.05M	12.86M	9.70M	9.11M	7.44M	10.82M	9.29M	18.21M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.77M	10.09M	13.11M
Operating Income	-	-	-1.93M	-3.38M	-6.66M	-10.89M	-27.66M	-48.16M	-38.97M	-21.29M	-26.32M	-28.83M	-50.51M	-92.31M	-112.09M	-118.38M	-136.70M	-125.70M
Net Income	-202.00K	-221.00K	-1.96M	-3.47M	-9.45M	-10.88M	-27.62M	-48.05M	-38.84M	-21.12M	-26.09M	-28.62M	-50.46M	-92.29M	-110.22M	-116.66M	-130.04M	-124.02M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-8.10	-20.01	-14,720.25	-176.60	-14.57
R&D Expense	-	-	584.30K	1.16M	2.58M	4.65M	18.62M	35.50M	28.53M	13.34M	17.56M	18.19M	36.16M	68.84M	81.88M	86.66M	39.97M	44.49M

Balance Sheet (Annual)

Figures in USD.

Metric	May 2007	Jun 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	184.00K	425.45K	2.12M	8.74M	39.54M	47.02M	27.51M	26.75M	26.32M	14.56M	98.18M	240.90M	225.69M	154.46M	162.89M	277.17M
Total Equity	0	0	-415.00K	-545.00K	-537.00K	-175.00K	-2.45M	959.00K	6.51M	36.09M	40.26M	25.36M	24.62M	23.66M	9.42M	87.65M	218.72M	207.18M	105.53M	139.56M	245.15M
Cash & Equivalents	-	-	-	-	-	-	-	1.78M	8.20M	38.18M	19.18M	18.94M	25.50M	25.03M	11.25M	77.07M	178.66M	120.23M	24.95M	98.78M	207.64M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.56M	4.67M	-
Total Liabilities	-	-	-	-	-	359.45K	2.88M	1.16M	2.22M	3.45M	6.76M	2.15M	2.14M	2.65M	5.14M	10.54M	22.18M	18.51M	48.93M	23.33M	32.02M
Current Liabilities	-	-	-	-	-	340.28K	925.28K	1.14M	2.21M	3.38M	6.65M	2.12M	2.13M	2.65M	5.13M	9.82M	21.72M	18.18M	18.88M	18.31M	30.84M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.23M	-2.64M	-5.71M	-	-	-	-37.31M	-19.13M	-23.97M	-26.68M	-48.57M	-75.56M	-98.05M	-102.00M	-60.92M	-99.84M
Investing Cash Flow	-94.37K	302	-35.76K	-	-	-	16.55M	7.17M	-6.00K	-17.00K	-8.56M	-35.31M	-48.15M	-29.07M	-120.00K	-4.53M
Financing Cash Flow	1.39M	2.61M	7.49M	-	-	-	20.50M	18.52M	23.54M	12.92M	123.11M	212.49M	87.84M	36.52M	134.87M	214.53M
Capital Expenditure	-34.28K	-2.76K	-36.00K	-15.00K	-319.00K	-118.00K	-66.00K	-5.00K	-6.00K	-17.00K	-8.56M	-35.31M	-48.15M	-7.89M	-120.00K	-3.37M
Free Cash Flow	-1.27M	-2.64M	-5.75M	-	-	-	-37.38M	-19.13M	-23.98M	-26.70M	-57.13M	-110.86M	-146.20M	-109.90M	-61.05M	-103.21M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	13.96M	-	13.76M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,523.9%	-1,354.3%	-959.1%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,501.8%	-1,288.3%	-946.2%
ROE %	37.1%	41.2%	1,122.3%	141.4%	-985.4%	-167.1%	-76.5%	-119.4%	-153.2%	-85.8%	-110.2%	-303.9%	-57.6%	-42.2%	-53.2%	-110.6%	-93.2%	-50.6%
ROCE %	-	-	1,234.1%	675.9%	-680.5%	-166.9%	-76.5%	-119.3%	-153.5%	-86.5%	-111.2%	-305.9%	-57.2%	-42.1%	-54.0%	-87.3%	-94.5%	-51.0%

Shareholding Pattern

Insiders

0.13%

Institutions

45.54%

Public Float

45.60%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.07%	968.18K	$12.21M
2	Vanguard Capital Management LLC	3.25%	518.65K	$6.54M
3	Citadel Advisors Llc	2.94%	468.71K	$5.91M
4	Jones Hill Capital LP	2.84%	452.12K	$5.70M
5	Geode Capital Management, LLC	1.97%	313.29K	$3.95M
6	Balyasny Asset Management LP	1.96%	313.08K	$3.95M
7	UBS Group AG	1.45%	231.68K	$2.92M
8	State Street Corporation	1.45%	230.61K	$2.91M
9	Millennium Management Llc	1.38%	219.67K	$2.77M
10	AQR Capital Management, LLC	1.01%	161.21K	$2.03M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TNXP

Google News Mon, 13 Jul 2026

Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNZVhFMlRpZDNyOElYYmtxcWRrSTJYaHQzYXprd2Zuejc4R0EtX0Q4bzNRNC10NkZmel94NDdqYmhzVFBPbWhuVWMyZXEzVjgxTDZ0Uzdsd215WDRaNHI1SHdORS1OU1FITGhUcVhnSkl0THhYTkNwYW9YOF9sUUROMS01M3FZZG1PVEl6Mi…

Google News Mon, 13 Jul 2026

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5xYUdIdXc0dHRwdnBSLUk2VVRyaUxhVmRsQ09lTUJkclNsTXVXOEp0VnJIQnNEQXAtdHo0aUloeWoyZC1XSVZQZkFKSWtuc3kw?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>  <fon…

Google News Mon, 13 Jul 2026

Fibromyalgia drug TONMYA to reach 145M covered lives by 2027 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPRl9KXzhuYXd5cFNhQXFmc3BFdnlDZzRiWGpRNHh0MU5VbXdhTFJkZ3Y0YXUxM0ZQTklOMUI2blBSTHJrdE12MmU3RjRZM0hIUTg3OU5UR3F6TnNmZVpnM3NJQ0NuMk5mUG5COXZLeHd2QW1qUmpLWXNpWGE0a2oxaXBKV296QS1OREI5bE…

Google News ue, 14 Jul 2026

Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQTU02WnRFT1h3ZFhwaG9LLUc5eGd1T195R0pGOTRRaUk0clh6QnZiZzY0SXRWcmtTMGotT1QxbTY5bnBQY3RvbFB6YnBZdWRvVnlBOTg5UlBnQkFrZld1QkN1RzRxWE5idHRoTEhBeGNiRmlsWHloZFJQWWk2UVFDRXJodXNNb0xCYUVWU0…

Google News Mon, 13 Jul 2026

Tonix Pharmaceuticals (TNXP) Expands Medicare Coverage for Fibro - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOSHI4NG5FOTdvbF9QUTd4Y0VvQmt3TW5CbG5HdHpWaHVIdjVLX3A3bXJIbGdLSFdjTlRrR2F0QzR3alE2MU5pTG0wMkY4cUdXSWJ3MnJVR001TWhyeml5RHBXd2ZCUDd1QXJPQmNuQ0JHeGxnNG93dWFJNUhpdEhUOVdwaDl5UFB4OVNXcl…

Google News Sat, 13 Jun 2026

We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOVkRoYUF1U0tkbXEzYzF2VElfLTcweEtWRzZPUGpFbUJiWUhncHRkd3F1bWJPSTFCdG1FSVVzZGh3OUsxX1BkazU0dGRwNVNvaWRiazFHWndwUDRjeDY4N3BhT2FmM3F2VjhFcGI5VF9LMUh3MDJJQmU0a2xST2YtTzdUVXRlOXJXNWdwbz…

TNXP — Frequently Asked Questions

What is the current share price of Tonix Pharmaceuticals Holding Corp. (TNXP)?

As of 2026-07-14 21:23 PDT, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at $11.06 on NasdaqGS. Its 52-week range is $10.65 to $61.57.

What is the market capitalisation of TNXP?

Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalisation of $176.31M on NasdaqGS.

What is the P/E ratio of TNXP?

TNXP trades at a trailing price-to-earnings (P/E) ratio of -0.75. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.59.

What is the return on equity (ROE) of TNXP?

TNXP has a return on equity (ROE) of -72.33%. Its return on capital employed (ROCE) is -51.03%.

Is TNXP a good stock to buy?

This page provides a data-driven analysis of Tonix Pharmaceuticals Holding Corp. (TNXP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Tonix Pharmaceuticals Holding Corp. TNXP R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits

symbol__ Stock Quote Price and Forecast - CNN

Fibromyalgia drug TONMYA to reach 145M covered lives by 2027 - Stock Titan

Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones - Stock Traders Daily

Tonix Pharmaceuticals (TNXP) Expands Medicare Coverage for Fibro - GuruFocus

We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate - Yahoo Finance

TNXP — Frequently Asked Questions

What is the current share price of Tonix Pharmaceuticals Holding Corp. (TNXP)?

What is the market capitalisation of TNXP?

What is the P/E ratio of TNXP?

What is the return on equity (ROE) of TNXP?

Is TNXP a good stock to buy?

Explore More